Cytokinetics (NASDAQ:CYTK) Price Target Raised to $85.00 at Needham & Company LLC

Cytokinetics (NASDAQ:CYTK) had its price target boosted by stock analysts at Needham & Company LLC from $84.00 to $85.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 21.26% from the company’s current price.

CYTK has been the subject of a number of other reports. JPMorgan Chase & Co. increased their price target on Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Citizens Jmp increased their price target on shares of Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $90.00 target price on shares of Cytokinetics in a report on Friday, January 9th. B. Riley Financial lifted their target price on Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, January 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Sixteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.78.

Cytokinetics Trading Up 2.7%

Shares of NASDAQ CYTK opened at $70.10 on Wednesday. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $70.98. The stock has a market cap of $8.57 billion, a PE ratio of -11.14 and a beta of 0.54. The company has a 50-day moving average of $64.14 and a 200 day moving average of $58.32.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.02). The business had revenue of $17.76 million during the quarter, compared to the consensus estimate of $8.02 million. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.26) EPS. On average, sell-side analysts forecast that Cytokinetics will post -5.24 EPS for the current fiscal year.

Insider Transactions at Cytokinetics

In other news, Director Wendell Wierenga sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the sale, the director directly owned 32,444 shares of the company’s stock, valued at $2,145,846.16. This trade represents a 38.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the sale, the executive vice president owned 138,552 shares of the company’s stock, valued at $8,484,924.48. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 151,385 shares of company stock valued at $9,817,158 over the last three months. 3.40% of the stock is owned by corporate insiders.

Institutional Trading of Cytokinetics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of Montreal Can increased its stake in shares of Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock worth $845,000 after purchasing an additional 160 shares during the period. Kennedy Capital Management LLC increased its position in Cytokinetics by 1.2% during the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock worth $838,000 after acquiring an additional 162 shares during the period. UMB Bank n.a. boosted its holdings in Cytokinetics by 10.6% in the 3rd quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 169 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares during the last quarter. Finally, Vident Advisory LLC increased its holdings in shares of Cytokinetics by 1.4% during the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after purchasing an additional 234 shares during the period.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe; U.S. launch underway with first prescriptions dispensed within days — this turns near-term revenue into a tangible commercial story and is the biggest immediate catalyst. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue materially exceeded expectations: Q4 revenue ~$17.7M vs. consensus near $8M — suggests early commercial uptake or other revenue sources are ahead of models. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Strong balance sheet: company reported ~ $1.2 billion in cash, cash equivalents and investments as of 12/31/25 and provided 2026 financial guidance — gives runway to support commercialization and ongoing trials. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Near-term clinical catalyst: company expects to share ACACIA‑HCM topline results in Q2 2026 — a positive binary event that could drive further re-rating if favorable. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst views are mixed on CYTK’s near-term outlook — some focus on commercial upside while others remain cautious on uptake and margins. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK) and Tandem Diabetes Care (TNDM)
• Neutral Sentiment: Full earnings and call transcripts are available for details on commercialization plans and cost structure; useful for investors who want management tone and phasing. Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Small EPS miss and widening loss: GAAP EPS was -$1.50 vs. consensus -$1.48, and the loss increased versus prior year (-$1.26) — ongoing operating losses remain a drag until revenue scales. Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.